KRAS Mutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing
´ëÇѺ´¸®ÇÐȸÁö 2014³â 48±Ç 2È£ p.100 ~ p.107
À̺¸¶÷(Lee Bo-Ram) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Pathology
À̺¸ÀÎ(Lee Bo-In) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Pathology
(Han Gang-Min) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Pathology
±Ç¹ÌÁ¤(Kwon Mi-Jung) - Hallym University College of Medicine Hallym University Sacred Heart Hospital Department of Pathology
ÇÑÁ¤È£(Han Joung-Ho) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Pathology
ÃÖÀ±¶ó(Choi Yoon-La) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Pathology
Abstract
Background: KRAS is one of commonly mutated genetic ¡°drivers¡± in non-small cell lung cancers (NSCLCs). Recent studies indicate that patients with KRAS-mutated tumors do not benefit from adjuvant chemotherapy, so there is now a focus on targeting KRAS-mutated NSCLCs. A feasible mutation detection method is required in order to accurately test for KRAS status.
Methods: We compared direct Sanger sequencing and the peptide nucleic acid (PNA)-mediated polymerase chain reaction (PCR) clamping method in 134 NSCLCs and explored associations with clinicopathological factors. Next-generation sequencing (NGS) was used to validate the results of discordant cases. To increase the resolution of low-level somatic mutant molecules, PNA-mediated PCR clamping was used for mutant enrichment prior to NGS.
Results: Twenty-one (15.7%) cases were found to have the KRAS mutations using direct sequencing, with two additional cases by the PNA-mediated PCR clamping method. The frequencies of KRAS mutant alleles were 2% and 4%, respectively, using conventional NGS, increasing up to 90% and 89%, using mutant-enriched NGS. The KRAS mutation occurs more frequently in the tumors of smokers (p=.012) and in stage IV tumors (p=.032).
Conclusions: Direct sequencing can accurately detect mutations, but, it is not always possible to obtain a tumor sample with sufficient volume. The PNA-mediated PCR clamping can rapidly provide results with sufficient sensitivity.
Å°¿öµå
Lung neoplasms, KRAS, Mutation, Peptide nucleic acids
KMID :
0357920140480020100
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)